Nuvectra (NVTR) Releases Quarterly Earnings Results, Misses Estimates By $0.18 EPS

Share on StockTwits

Nuvectra (NASDAQ:NVTR) issued its quarterly earnings data on Wednesday. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.18), Bloomberg Earnings reports. Nuvectra had a negative net margin of 91.74% and a negative return on equity of 60.14%. The firm had revenue of $11.13 million for the quarter, compared to the consensus estimate of $12.76 million.

Shares of NASDAQ NVTR traded down $0.12 during midday trading on Friday, hitting $6.01. 3,108 shares of the company traded hands, compared to its average volume of 218,533. Nuvectra has a 12-month low of $5.91 and a 12-month high of $25.17. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.81 and a quick ratio of 5.48. The stock has a market capitalization of $167.96 million, a P/E ratio of -1.88 and a beta of -0.18.

Several brokerages recently issued reports on NVTR. JMP Securities reduced their price target on shares of Nuvectra from $26.00 to $18.00 and set an “outperform” rating on the stock in a research report on Thursday. They noted that the move was a valuation call. ValuEngine cut shares of Nuvectra from a “hold” rating to a “sell” rating in a research report on Friday. BidaskClub upgraded shares of Nuvectra from a “sell” rating to a “hold” rating in a research report on Wednesday, February 20th. Finally, Raymond James reduced their price target on shares of Nuvectra from $23.00 to $18.00 and set an “outperform” rating on the stock in a research report on Friday, March 1st. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $20.40.

Several hedge funds and other institutional investors have recently made changes to their positions in NVTR. BNP Paribas Arbitrage SA purchased a new position in shares of Nuvectra during the first quarter valued at about $40,000. PNC Financial Services Group Inc. increased its position in shares of Nuvectra by 231.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,318 shares of the company’s stock valued at $54,000 after buying an additional 2,318 shares during the period. Metropolitan Life Insurance Co. NY increased its position in shares of Nuvectra by 356.5% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 5,108 shares of the company’s stock valued at $83,000 after buying an additional 3,989 shares during the period. American International Group Inc. increased its position in shares of Nuvectra by 23.5% during the fourth quarter. American International Group Inc. now owns 11,394 shares of the company’s stock valued at $186,000 after buying an additional 2,166 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in shares of Nuvectra during the third quarter valued at about $201,000. Institutional investors own 80.39% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was first published by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://weekherald.com/2019/05/03/nuvectra-nvtr-releases-quarterly-earnings-results-misses-estimates-by-0-18-eps.html.

Nuvectra Company Profile

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.

Further Reading: Compound Interest and Why It Matters When Investing

Earnings History for Nuvectra (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.